Cover Image
市場調查報告書

HIV/AIDS:開發平台分析

HIV / AIDS - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 232769
出版日期 內容資訊 英文 886 Pages
訂單完成後即時交付
價格
Back to Top
HIV/AIDS:開發平台分析 HIV / AIDS - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 886 Pages
簡介

HIV是攻擊免疫系統的病毒,減弱與感染疾病和疾病作戰的體內力量。症狀有發燒、喉嚨疼痛、身體發疹、關節痛、肌肉痛、腺體肥大等。HIV感染最容易擴大的是,不使用保險套跟HIV/AIDS感染者的陰道或肛門的性交,及與感染者共用針頭,用附有HIV的外科用器具在身體上造成深度傷口,感染HIV的血液、精液或陰道的分泌物進入開放性傷口等。

本報告提供HIV / AIDS 的治療藥開發平台現狀,及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • HIV / AIDS 概要

治療藥的開發

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7958IDB

Summary

Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H1 2016', provides an overview of the HIV / AIDS pipeline landscape.

The report provides comprehensive information on the therapeutics under development for HIV / AIDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for HIV / AIDS and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of HIV / AIDS
  • The report reviews pipeline therapeutics for HIV / AIDS by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved HIV / AIDS therapeutics and enlists all their major and minor projects
  • The report assesses HIV / AIDS therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for HIV / AIDS

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • HIV / AIDS Overview
  • Therapeutics Development
  • HIV / AIDS - Therapeutics under Development by Companies
  • HIV / AIDS - Therapeutics under Investigation by Universities/Institutes
  • HIV / AIDS - Pipeline Products Glance
  • HIV / AIDS - Products under Development by Companies
  • HIV / AIDS - Products under Investigation by Universities/Institutes
  • HIV / AIDS - Companies Involved in Therapeutics Development
  • HIV / AIDS - Therapeutics Assessment
  • Drug Profiles
  • HIV / AIDS - Dormant Projects
  • HIV / AIDS - Discontinued Products
  • HIV / AIDS - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for HIV / AIDS, H1 2016
  • Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)
  • HIV / AIDS - Pipeline by Abivax S.A., H1 2016
  • HIV / AIDS - Pipeline by AdAlta Pty Ltd., H1 2016
  • HIV / AIDS - Pipeline by Advanced Genetic Systems, Inc., H1 2016
  • HIV / AIDS - Pipeline by Akshaya Bio Inc., H1 2016
  • HIV / AIDS - Pipeline by AlbaJuna Therapeutics, H1 2016
  • HIV / AIDS - Pipeline by Altor BioScience Corporation, H1 2016
  • HIV / AIDS - Pipeline by Altravax, Inc., H1 2016
  • HIV / AIDS - Pipeline by Amarna Therapeutics B.V., H1 2016
  • HIV / AIDS - Pipeline by American Gene Technologies International Inc., H1 2016
  • HIV / AIDS - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Amunix Operating Inc. , H1 2016
  • HIV / AIDS - Pipeline by Antigen Express, Inc., H1 2016
  • HIV / AIDS - Pipeline by Aphios Corporation, H1 2016
  • HIV / AIDS - Pipeline by Apotex Inc., H1 2016
  • HIV / AIDS - Pipeline by Argos Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Arno Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Avexa Limited, H1 2016
  • HIV / AIDS - Pipeline by BCI Pharma, H1 2016
  • HIV / AIDS - Pipeline by BioClonetics Immunotherapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Bionor Pharma ASA, H1 2016
  • HIV / AIDS - Pipeline by Biosantech SA, H1 2016
  • HIV / AIDS - Pipeline by Biotron Limited, H1 2016
  • HIV / AIDS - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • HIV / AIDS - Pipeline by C4X Discovery Holdings PLC, H1 2016
  • HIV / AIDS - Pipeline by CEL-SCI Corporation, H1 2016
  • HIV / AIDS - Pipeline by Celgene Corporation, H1 2016
  • HIV / AIDS - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • HIV / AIDS - Pipeline by CompleGen, Inc., H1 2016
  • HIV / AIDS - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • HIV / AIDS - Pipeline by CureVac GmbH, H1 2016
  • HIV / AIDS - Pipeline by Cytodyn Inc., H1 2016
  • HIV / AIDS - Pipeline by Enzo Biochem, Inc., H1 2016
  • HIV / AIDS - Pipeline by EpiVax, Inc., H1 2016
  • HIV / AIDS - Pipeline by eTheRNA Immunotherapies NV, H1 2016
  • HIV / AIDS - Pipeline by Etubics Corporation, H1 2016
  • HIV / AIDS - Pipeline by Evofem, Inc., H1 2016
  • HIV / AIDS - Pipeline by FIT Biotech Oy, H1 2016
  • HIV / AIDS - Pipeline by Formune S.L., H1 2016
  • HIV / AIDS - Pipeline by Fountain Biopharma Inc., H1 2016
  • HIV / AIDS - Pipeline by Frontier Biotechnologies Co., Ltd, H1 2016
  • HIV / AIDS - Pipeline by GeneCure LLC, H1 2016
  • HIV / AIDS - Pipeline by Genetic Immunity, Inc, H1 2016
  • HIV / AIDS - Pipeline by Genticel S.A., H1 2016
  • HIV / AIDS - Pipeline by GeoVax Labs, Inc., H1 2016
  • HIV / AIDS - Pipeline by Gilead Sciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by GlaxoSmithKline Plc, H1 2016
  • HIV / AIDS - Pipeline by Globeimmune, Inc., H1 2016
  • HIV / AIDS - Pipeline by H-Phar S.A., H1 2016
  • HIV / AIDS - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016
  • HIV / AIDS - Pipeline by Heat Biologics, Inc., H1 2016
  • HIV / AIDS - Pipeline by iCo Therapeutics Inc., H1 2016
  • HIV / AIDS - Pipeline by ID Pharma Co., Ltd., H1 2016
  • HIV / AIDS - Pipeline by Immune Response BioPharma, Inc., H1 2016
  • HIV / AIDS - Pipeline by Immunocore Limited, H1 2016
  • HIV / AIDS - Pipeline by ImQuest Life Sciences, H1 2016
  • HIV / AIDS - Pipeline by InnaVirVax SA, H1 2016
  • HIV / AIDS - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Japan Tobacco Inc., H1 2016
  • HIV / AIDS - Pipeline by Johnson & Johnson, H1 2016
  • HIV / AIDS - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016
  • HIV / AIDS - Pipeline by Longevity Biotech, Inc, H1 2016
  • HIV / AIDS - Pipeline by MacroGenics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • HIV / AIDS - Pipeline by Medivir AB, H1 2016
  • HIV / AIDS - Pipeline by Merck & Co., Inc., H1 2016
  • HIV / AIDS - Pipeline by Mologen AG, H1 2016
  • HIV / AIDS - Pipeline by Mymetics Corporation, H1 2016
  • HIV / AIDS - Pipeline by Myrexis, Inc., H1 2016
  • HIV / AIDS - Pipeline by NanoBio Corporation, H1 2016
  • HIV / AIDS - Pipeline by NanoViricides, Inc., H1 2016
  • HIV / AIDS - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by NeED Pharma s.r.l., H1 2016
  • HIV / AIDS - Pipeline by New World Laboratories, Inc., H1 2016
  • HIV / AIDS - Pipeline by Novartis AG, H1 2016
  • HIV / AIDS - Pipeline by Omeros Corporation, H1 2016
  • HIV / AIDS - Pipeline by Oncolys BioPharma Inc., H1 2016
  • HIV / AIDS - Pipeline by OncoNOx ApS, H1 2016
  • HIV / AIDS - Pipeline by Oncovir, Inc., H1 2016
  • HIV / AIDS - Pipeline by Orbis Biosciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Osel, Inc., H1 2016
  • HIV / AIDS - Pipeline by OyaGen Inc., H1 2016
  • HIV / AIDS - Pipeline by PaxVax, Inc., H1 2016
  • HIV / AIDS - Pipeline by Pepscan Therapeutics, H1 2016
  • HIV / AIDS - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Pfizer Inc., H1 2016
  • HIV / AIDS - Pipeline by Pharis Biotec GmbH, H1 2016
  • HIV / AIDS - Pipeline by Pharmsynthez, H1 2016
  • HIV / AIDS - Pipeline by Phoenix Biotechnology, Inc., H1 2016
  • HIV / AIDS - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2016
  • HIV / AIDS - Pipeline by Presidio Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Profectus BioSciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by ReceptoPharm, Inc., H1 2016
  • HIV / AIDS - Pipeline by Rodos BioTarget GmbH, H1 2016
  • HIV / AIDS - Pipeline by Sangamo BioSciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Sanofi, H1 2016
  • HIV / AIDS - Pipeline by Sanofi Pasteur SA, H1 2016
  • HIV / AIDS - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by SEEK Group, H1 2016
  • HIV / AIDS - Pipeline by Serometrix, LLC, H1 2016
  • HIV / AIDS - Pipeline by Sirenas Marine Discovery LLC, H1 2016
  • HIV / AIDS - Pipeline by Spider Biotech, H1 2016
  • HIV / AIDS - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
  • HIV / AIDS - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016
  • HIV / AIDS - Pipeline by Starpharma Holdings Limited, H1 2016
  • HIV / AIDS - Pipeline by Susavion Biosciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Taiga Biotechnologies, Inc., H1 2016
  • HIV / AIDS - Pipeline by TaiMed Biologics Inc., H1 2016
  • HIV / AIDS - Pipeline by Takara Bio Inc., H1 2016
  • HIV / AIDS - Pipeline by TechnoVax, Inc., H1 2016
  • HIV / AIDS - Pipeline by TeneoBio Inc, H1 2016
  • HIV / AIDS - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • HIV / AIDS - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • HIV / AIDS - Pipeline by TGV-Laboratories, H1 2016
  • HIV / AIDS - Pipeline by Theraclone Sciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Theravectys SA, H1 2016
  • HIV / AIDS - Pipeline by Tobira Therapeutics, Inc., H1 2016
  • HIV / AIDS - Pipeline by Tomegavax, Inc., H1 2016
  • HIV / AIDS - Pipeline by Transgene Biotek Limited, H1 2016
  • HIV / AIDS - Pipeline by TVAX Biomedical, Inc., H1 2016
  • HIV / AIDS - Pipeline by United Biomedical, Inc., H1 2016
  • HIV / AIDS - Pipeline by United Therapeutics Corporation, H1 2016
  • HIV / AIDS - Pipeline by Vaccibody AS, H1 2016
  • HIV / AIDS - Pipeline by Vault Pharma Inc., H1 2016
  • HIV / AIDS - Pipeline by VDA Pharma, Inc., H1 2016
  • HIV / AIDS - Pipeline by VG Life Sciences, Inc., H1 2016
  • HIV / AIDS - Pipeline by Vichem Chemie Research Ltd., H1 2016
  • HIV / AIDS - Pipeline by ViiV Healthcare Limited, H1 2016
  • HIV / AIDS - Pipeline by Viriom Ltd., H1 2016
  • HIV / AIDS - Pipeline by ViroStatics srl, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • HIV / AIDS - Dormant Projects, H1 2016
  • HIV / AIDS - Dormant Projects (Contd..1), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..2), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..3), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..4), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..5), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..6), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..7), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..8), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..9), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..10), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..11), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..12), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..13), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..14), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..15), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..16), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..17), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..18), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..19), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..20), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..21), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..22), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..23), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..24), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..25), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..26), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..27), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..28), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..29), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..30), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..31), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..32), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..33), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..34), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..35), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..36), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..37), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..38), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..39), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..40), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..41), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..42), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..43), H1 2016
  • HIV / AIDS - Dormant Projects (Contd..44), H1 2016
  • HIV / AIDS - Discontinued Products, H1 2016
  • HIV / AIDS - Discontinued Products (Contd..1), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..2), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..3), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..4), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..5), H1 2016
  • HIV / AIDS - Discontinued Products (Contd..6), H1 2016

List of Figures

  • Number of Products under Development for HIV / AIDS, H1 2016
  • Number of Products under Development for HIV / AIDS - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top